PMV hopes for rezatapopt redemption
The disappointing Pynnacle trial is set to yield registrational data.
Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Pivotal T-cell engager readouts approach
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Another first-in-human mystery from Merck
MK-8294 starts phase 1, but its mechanism is anybody's guess.
More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
When two antigens are better than one
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
Chia Tai broadens its biparatopic breast cancer approach
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
